{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:18:28Z","timestamp":1707524308306},"reference-count":6,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,1]]},"DOI":"10.7759\/cureus.15367","type":"journal-article","created":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T13:11:57Z","timestamp":1622553117000},"source":"Crossref","is-referenced-by-count":0,"title":["Left Atrial Appendage Occlusion: A Therapeutic Option in a Patient With Atrial Fibrillation and Hereditary Hemorrhagic Telangiectasia"],"prefix":"10.7759","author":[{"given":"Luciana","family":"Frade","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e1udio","family":"Gouveia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato","family":"Guerreiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Jesus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Candida","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Epistaxis repetees chez un sujet porteur de petits angiomes cutan\u00b4es et muqueux","volume":"13","author":"Rendu M","year":"1896","unstructured":"Rendu M. Epistaxis repetees chez un sujet porteur de petits angiomes cutan\u00b4es et muqueux. Bull Mem Soc Med Hop Paris. 1896, 13:731-3.","journal-title":"Bull Mem Soc Med Hop Paris"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2016.04.006","article-title":"Reported cardiac phenotypes in hereditary hemorrhagic telangiectasia emphasize burdens from arrhythmias, anemia and its treatments, but suggest reduced rates of myocardial infarction","volume":"215","author":"Shovlin CL","year":"2016","unstructured":"Shovlin CL, Awan I, Cahilog Z, Abdulla FN, Guttmacher AE. Reported cardiac phenotypes in hereditary hemorrhagic telangiectasia emphasize burdens from arrhythmias, anemia and its treatments, but suggest reduced rates of myocardial infarction. Int J Cardiol. 2016, 215:179-85. 10.1016\/j.ijcard.2016.04.006","journal-title":"Int J Cardiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks G","year":"2021","unstructured":"Hindricks G, Potpara T, Dagres N, et al.. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021, 42:373-498. 10.1093\/eurheartj\/ehaa612","journal-title":"Eur Heart J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1213554","article-title":"Antiplatelet and anticoagulant agents in hereditary hemorrhagic telangiectasia","volume":"368","author":"Devlin HL","year":"2013","unstructured":"Devlin HL, Hosman AE, Shovlin CL. Antiplatelet and anticoagulant agents in hereditary hemorrhagic telangiectasia. N Engl J Med. 2013, 368:876-8. 10.1056\/NEJMc1213554","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/eux254","article-title":"Left atrial appendage occluder implantation in Europe: indications and anticoagulation post-implantation. Results of the European Heart Rhythm Association Survey","volume":"19","author":"Tilz RR","year":"2017","unstructured":"Tilz RR, Potpara T, Chen J, Dobreanu D, Larsen TB, Haugaa KH, Dagres N. Left atrial appendage occluder implantation in Europe: indications and anticoagulation post-implantation. Results of the European Heart Rhythm Association Survey. Europace. 2017, 19:1737-42. 10.1093\/europace\/eux254","journal-title":"Europace"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.15420\/icr.2015.10.2.109","article-title":"Real world outcomes of left atrial appendage occlusion","volume":"10","author":"Tzikas A","year":"2015","unstructured":"Tzikas A, Mylotte D, Bergmann M. Real world outcomes of left atrial appendage occlusion. Interv Cardiol. 2015, 10:109-11. 10.15420\/icr.2015.10.2.109","journal-title":"Interv Cardiol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/61262-left-atrial-appendage-occlusion-a-therapeutic-option-in-a-patient-with-atrial-fibrillation-and-hereditary-hemorrhagic-telangiectasia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:29:27Z","timestamp":1707506967000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/61262-left-atrial-appendage-occlusion-a-therapeutic-option-in-a-patient-with-atrial-fibrillation-and-hereditary-hemorrhagic-telangiectasia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,1]]},"references-count":6,"URL":"https:\/\/doi.org\/10.7759\/cureus.15367","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6,1]]}}}